Follow Ciliatech’s past history and latest exciting developments via the news stories below.
Ciliatech presents preliminary one-year study results on treating open and narrow angle glaucoma with CID at Ophthalmology Futures Symposium. Preliminary 12-month results show excellent performance and safety profile CID glaucoma implant works similarly in both open and narrow angle glaucoma patients, without the need to remove lens 86% of patients
You will be the 2nd employee of the Company, reporting directly to the CEO, and in close connection with the medical Director.
Prevalence of glaucoma Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form, Primary Open-Angle Glaucoma (POAG), affects more than 3% of people aged 40 years or older. Prevalence increases with age. In people
At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID). The device, a 26% hydrophilic acrylic implant, is designed to lower intraocular pressure without entering the anterior chamber and without
Results from second CID (Cilio-scleral Interposition Device) study confirm sustained decrease in intraocular pressure (IOP), while preserving anterior chamber of eye Clinical data on CID, the first in a new category of glaucoma implants, will be shared during World Glaucoma Congress in Rome, June 28 to July 2, 2023. Chavanod
This site is only for the use of professionals associated with the field of Ophthalmology and is not intended for patients.
